medigraphic.com

2001, Number 1

<< Back Next >>

Rev Fac Med UNAM 2001; 44 (1)

Vastatines: cholesterol biosynthesis inhibitors: efficiency and toxicity

Piedras HMA, Asenjo BJC, Miranda ZR, Juárez OMA, Díaz ZJC

Language: Spanish
References: 25
Page: 12-17
PDF size: 52.62 Kb.


Text Extraction

No abstract


REFERENCES

  1. Siperstein MD, Fagan VM. Feedback control of mevalonate synthesis by dietary cholesterol J Biol Chem 1966; 241: 602 - 9.

  2. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 1992; 33: 1569 - 82.

  3. Clerc T, Jomier M, Chautan M y col. Mechanisms of action in the liver of crilvastatin, a new hydroxymethylglutaryl-coenzime A reductase inhibitor. Eur J Pharmacol 1993; 235: 59 - 68.

  4. Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127 - 31.

  5. Lescol. Indicaciones terapéuticas. Monografía 6 - 9. Temas Destacados en Clínica Médica 1996; 1: 14 - 15.

  6. Ciarovino BV, Kropko ML, Rothwell CE, Hovey CA, Theiss JC. The genotoxicity profile of atorvastatin, a new drug in the treatment of hypercholesterolemia. Mutation Res 1995; 343: 95 - 107.

  7. Grupo Warmen Lambert de México, SA de CV. Atorvastatin: lipitor. Monografía Pag 1 - 59.

  8. Clerc T, Sbarra V, Diaconescu N y col. Effect of crilvastatin, a new cholesterol lowering agent, on unesterified LDL-cholesterol metabolism into bile salts by rat isolated hepatocytes. British J Pharmacol 1995; 114: 624 - 31.

  9. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21A - 28A.

  10. Yuan J, Tsai MY, Hegland J, Hunninghate B. Effects of fluvastatin (XU 62-320), a HMG-CoA reductase inhibitor, on the distribution and composition of low density lipoprotein subspecies in humans. Atherosclerosis 1991; 87: 147 - 57.

  11. Eichstädt HW, Eskötter H, Hoffmann I, Amthauer HW, Weidinger G. Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995; 76: 122A - 125A.

  12. Spence JD, Munoz CE, Hendricks L, Latchinian L, Khouri HE. Pharmacokinetics of the combination of fluvastatin and gemfibrozil. Am J Cardiol 1995; 76: 80 - 83A.

  13. Koizumi J, Haraki T, Yagy K y col. Clinical efficacy of fluvastatin in the long-term treatment of familial hypercholesterolemia. Am J Cardiol 1995; 76: 47A - 50A.

  14. Hajri T, Férézou J, Larvelle C, Lutton C. Crilvastatin, a new 3-hydroxy-3-methyglutaryl-coenzyme. A reductase inhibitor, inhibits cholesterol absorption in genetically hypercholesterolemic rats. Eur J Pharmacol 1995; 286: 131 - 6.

  15. Nakahara K, Kuriyama M, Sonoda Y, Yoshidome H, Nakagawa H, Fujiyama J, Higuchi I, Osame M. Myopathy induced by HMG-CoA reductase inhibitors in rabbits: a pathological, electrophysiological, and biochemical study. Toxicol Appl Pharmacol 1998; 152: 99 - 106.

  16. Gotto AM, Pownall HJ. Los trastornos lipídicos en la práctica clínica. Waverly Hispánica S.A. Buenos Aires, 1995; 109 - 12.

  17. Appel S, Rüfenacht T, Kalafsky G y col. Lack of interaction between fluvastatina and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus. Am J Cardiol 1995; 76: 29A - 32A.

  18. Brown MS, Goldstein JL. Heart attacks: gone with the century? Science 1996; 272: 629.

  19. MacDonald JS, Gernson RJ, Kornbrust DJ y col. Preclinical evaluation of lovastatin. Am J Cardiol 1988; 62: 16J - 27J.

  20. Jackson SM, Ericsson J, Edwards PA. Signaling molecules derived from the cholesterol biosynthetic pathway. En Subcellular Biochemistry, Vol. 28, Cholesterol: its functions and metabolism in biology and medicine. Editor R Bittman, Ed. Plenum Press NY, 1997: 1 - 21.

  21. Tint SG, Irons M, Elias ER, Batta AK, Frieden R, Chen TS, Salen G. Dfective cholesterol biosynthesis associated with the Smith-Lemli- Opitz syndrome. New Eng J Med 1994; 330: 107 – 113.

  22. Cooper MK, Porter JA, Young KE, Beachy PA. Teratogen-mediated inhibition of target tissue response to SHh signaling. Science 1998; 280: 1603 - 7.

  23. Asenjo-Barrón JC, Cárdenas-Vázquez R, Martínez F, Juárez-Oropeza MA, Díaz-Zagoya JC. High lovastatin doses associated to hypercholesterolemic diet induce hepatic damage and are lethal to CD-1 mouse. Life Sciences 1999; 64: 2155 - 2161.

  24. Díaz-Zagoya JC, Asenjo-Barrón JC, Cárdenas-Vázquez R, Martínez F, Juárez-Oropeza MA. Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet. Life Sciences 1999; 65: 947 - 956.

  25. Mundy G, Garret R, Harris S, Chan J, Chen D, Rossini G, Boyce B, Zhao M, Gutiérrez G. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286: 1946 - 1949.




2020     |     www.medigraphic.com